Business Context and Reporting Period
Company: 22nd Century Group, Inc. (XXII)
Filing Type: Form 8-K (Current Report)
Date of Report: May 13, 2022
Event: Completion of acquisition of GVB Biopharma ("GVB") assets related to hemp-based cannabinoid extraction, refinement, contract manufacturing, and product development.
Key Financial Metrics and Transaction Consideration
This filing details a specific transaction rather than periodic financial results. The aggregate consideration for the acquisition of GVB assets consisted of:
- Debt Assumption: Approximately $4.5 million.
- Transaction Costs: Assumption and direct payment of approximately $1.9 million in third-party costs incurred by GVB.
- Equity Issuance: 32,900,000 unregistered shares of common stock issued to GVB.
Note: The filing text does not provide clear values for the Company's standalone revenue, profit, cash flow, margins, or liquidity metrics for the reporting period.
Material Changes and Transaction Structure
The primary material change is the expansion of the Company's business through the acquisition of GVB's hemp-based cannabinoid assets. Key structural elements include:
- Share Restrictions: The 32.9 million shares issued are subject to a lock-up. One-third releases after six months, one-third after nine months, and the remainder after one year.
- Corporate Governance: GVB receives the right to nominate an independent director to the Company's board, subject to approval by the Governance and Nominating Committee.
- Employment: The Company has entered into employment arrangements with certain key employees of GVB.
Guidance, Outlook, and Disclosures
Regulation FD Disclosure: The Company issued press releases on May 13 and May 18, 2022, announcing the closing and detailing the operational capabilities of the combined business. These documents are incorporated by reference.
Financial Statements: Audited and unaudited financial statements of the acquired business, as well as pro forma financial information, are not included in this filing. The Company undertook to file these by amendment no later than 71 calendar days after the filing date.
Risks and Contingencies: The filing references customary representations, warranties, and covenants in the Reorganization Agreement but does not explicitly detail specific risks or contingencies beyond the standard transaction terms.
Investor Verification Checklist
- Verify the final terms of the Reorganization and Acquisition Agreement (Exhibit 2.1) for specific covenants and conditions.
- Review the upcoming 71-day amendment for the audited financial statements of GVB and pro forma financial information to assess the combined entity's financial health.
- Confirm the status of the $4.5 million debt assumption and the $1.9 million transaction cost payments.
- Monitor the lock-up schedule for the 32.9 million newly issued shares to understand future dilution and liquidity impacts.
- Review the May 18, 2022 presentation (Exhibit 99.3) for management's specific operational outlook and synergy projections.